RxDoctor Payments Data

Steven Couch, MD

Ophthalmology · Saint Louis, MONPI 1578590634

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 95.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $525 and has fallen 90.4% since, to $50 in 2025. That places this record below the midpoint for ophthalmology clinicians in MO, where the typical reported total is $1,365.

$1,051in general payments, 2019–2025

Across 21 payments — averaging $50.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • ANI Pharmaceuticals, Inc.$50
$1,167,444in research payments, 2019–2025

Across 10 payments — averaging $116,744 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$1.2M

What the payments were for

  • Consulting fees$656%
  • Food & beverage$98694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen20$1,000
ANI Pharmaceuticals, Inc.1$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,051 in reported general payments places this provider in the 40th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$279,010
Medicare patients
393
Services billed
9,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base393$3,602
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$248
Ondansetron OdtOndansetron18$149
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$95
Prednisone19$71

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →